Medicines360

Medicines360 Licenses Novel Stillbirth Risk Assessment Technologies from Cambridge and Edinburgh Universities

- Medicines360 acquired global licensing rights to innovative maternal health technologies that predict conditions responsible for 50% of stillbirths, including blood biomarkers and retinal imaging. - The technologies were developed at University of Cambridge and University of Edinburgh through Wellcome Leap's $50 million In Utero program to improve gestational development prediction. - Cambridge's blood-based biomarkers can identify risks for fetal growth restriction, gestational diabetes, and preeclampsia, while Edinburgh's retinal imaging detects cardiovascular and metabolic changes. - The licensing advances Medicines360's M360 ASPIRE program, which aims to integrate these risk assessment tools into routine prenatal care to dramatically reduce global stillbirth rates.